Silver Book Fact

Lucentis to treat wet age-related macular degeneration (AMD)

An FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)–ranibizumab (Lucentis)–maintained vision in 95% of clinical trial participants and improved vision by 15 or more letters in approximately 25% to 34% of trial participants.

Rosenfeld P, Brown D, Heier J, Boyer D, et al. Ranibizumab for Neovascular Age-Related Macular Degeneration. N Engl J Med. 2006; 355(14): 1419-31. http://content.nejm.org/cgi/content/abstract/355/14/1419

Reference

Title
Ranibizumab for Neovascular Age-Related Macular Degeneration
Publication
N Engl J Med
Publication Date
2006
Authors
Rosenfeld P, Brown D, Heier J, Boyer D, et al
Volume & Issue
Volume 355, Issue 14
Pages
1419-31
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Because the resource use and direct cost of glaucoma treatment and management increases as the disease severity worsens– from an average $623 per early-stage patient to $2,511 per late-stage patient–…  
  • Laser treatment and vitrectomy reduce the risk of blindness in patients with severe diabetic retinopathy by 90%.  
  • The cost-effectiveness of detection and treatment of eye disease in diabetics is $3,190 per quality adjusted life year (QALY).  
  • Current treatments for proliferative diabetic retinopathy have reduced the rate of blindness within 5 years from 50% to less than 5%.  
  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.